The aim is to be able to predict the hormonal response according to gonadotropin receptor genotype and hormone type used for treatment of women undergoing in vitro fertilization or egg donation. Outcome will be measured as pregnancy success, live born babies and unwanted side effects.
Name: Follitropin alpha
Description: The objective is to measure the effect of the drug according to gonadotropin receptor genotype.Type: DrugFollitropin alpha Menotropin
Name: Menotropin
Description: The objective is to measure the effect of the drug according to gonadotropin receptor genotype.Type: DrugFollitropin alpha Menotropin
Description: Association between pregnancy rate and genotype is evaluated
Measure: Pregnancy Time: up to 12 months after treatmentDescription: Number of eggs developed in response to drug according to genotype is measured
Measure: Number of oocytes Time: up to 6 months after treatmentDescription: Live birth rate according to genotype is analyzed
Measure: live birth Time: up to 12 months after treatmentDescription: Association between overreaction to hormonal stimulation and genotype is analysed
Measure: Ovarian hyper stimulation syndrome Time: Up to 6 months after treatmentDescription: No or poor development of eggs in response to drug is analysed, genotype taken into account
Measure: Poor response Time: Up to 6 months after treatmentAllocation: Randomized
Parallel Assignment
There are 2 SNPs
This assumption is supported by a recent study on more than 600 women undergoing in vitro fertilization, demonstrating that whereas only 10% of women with asparagine in both genes (FSHR N680S and LHR N312S) became pregnant, 40% of those with serine did (Lindgren I et al. --- N680S --- --- N312S ---
This assumption is supported by a recent study on more than 600 women undergoing in vitro fertilization, demonstrating that whereas only 10% of women with asparagine in both genes (FSHR N680S and LHR N312S) became pregnant, 40% of those with serine did (Lindgren I et al. --- N680S ---